Literature DB >> 32246771

Persistent Hyperactivation of Endothelial Cells in Patients with Alcoholic Hepatitis.

Ying Xia1,2,3, Jing Yang2,3, Arun J Sanyal4, Vijay H Shah5, Naga P Chalasani6, Qigui Yu3, Xiaoqun Zheng1,2, Wei Li3.   

Abstract

BACKGROUND: Alcoholic hepatitis (AH) is a severe inflammatory liver disease that develops in some heavy drinkers. AH patients have intense hepatic infiltration of leukocytes. Up-regulation of cell adhesion molecules (CAMs) upon endothelial cell (EC) activation plays an important role in leukocyte transendothelial migration. CAMs can shed from EC surface and accumulate in the blood, serving as soluble markers for EC activation. In this study, we examined the impact of heavy drinking on expression of soluble forms of EC activation markers (CD146, ICAM-1, VCAM-1, and VEGF-A) and the effect of alcohol abstinence on the reversal of these abnormalities in heavy drinkers with and without AH.
METHODS: ELISA and multiplex immunoassays were used to measure soluble EC activation markers in plasma samples from 79 AH patients, 66 heavy drinkers without overt liver disease (HDC), and 44 healthy controls (HC) at baseline, 31 AH patients and 30 HDC at 6-month follow-up, and 18 AH patients and 25 HDC at 12-month follow-up.
RESULTS: At baseline, the 4 soluble markers were significantly up-regulated in AH patients compared with HDC and HC, whereas only sVCAM-1 was elevated in HDC relative to HC. At follow-ups, plasma levels of CD146, VCAM-1, and VEGF-A remained higher in AH patients, even for those who stopped drinking. These dysregulated markers correlated with AH disease severity, clinical parameters, and several soluble inflammatory factors.
CONCLUSIONS: The levels of soluble CD146, ICAM-1, VCAM-1, and VEGF-A were highly elevated in AH patients, and alcohol abstinence did not completely reverse these abnormalities.
© 2020 by the Research Society on Alcoholism.

Entities:  

Keywords:  Adhesion Markers; Alcoholic Hepatitis; Endothelial Activation; Longitudinal Study; Soluble Forms

Year:  2020        PMID: 32246771      PMCID: PMC7255105          DOI: 10.1111/acer.14331

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  59 in total

1.  Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis: a prospective cohort study.

Authors:  Thomas Damgaard Sandahl; Henning Grønbaek; Holger Jon Møller; Sidsel Støy; Karen Luise Thomsen; Anders Kirch Dige; Jørgen Agnholt; Stephen Hamilton-Dutoit; Steffen Thiel; Hendrik Vilstrup
Journal:  Am J Gastroenterol       Date:  2014-08-26       Impact factor: 10.864

2.  Soluble CD146, a novel endothelial marker, is related to the severity of liver disease.

Authors:  Efrossini Nomikou; Alexandra Alexopoulou; Larisa Vasilieva; Danai Agiasotelli; Efthimia Pavlou; George Theodossiades; Spyridon P Dourakis
Journal:  Scand J Gastroenterol       Date:  2015-01-30       Impact factor: 2.423

3.  Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells.

Authors:  I Kim; S O Moon; S H Kim; H J Kim; Y S Koh; G Y Koh
Journal:  J Biol Chem       Date:  2000-12-06       Impact factor: 5.157

4.  Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies.

Authors:  Dominique Figarella-Branger; Nicolas Schleinitz; Brigitte Boutière-Albanèse; Laurence Camoin; Nathalie Bardin; Sandrine Guis; Jean Pouget; Céline Cognet; Jean-François Pellissier; Françoise Dignat-George
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

5.  Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia.

Authors:  Karim Harhouri; Abdeldjalil Kebir; Benjamin Guillet; Alexandrine Foucault-Bertaud; Serge Voytenko; Marie-Dominique Piercecchi-Marti; Caroline Berenguer; Edouard Lamy; Frédéric Vely; Pascale Pisano; L'houcine Ouafik; Florence Sabatier; José Sampol; Nathalie Bardin; Françoise Dignat-George; Marcel Blot-Chabaud
Journal:  Blood       Date:  2010-02-25       Impact factor: 22.113

Review 6.  Gender differences in risk factors and consequences for alcohol use and problems.

Authors:  Susan Nolen-Hoeksema
Journal:  Clin Psychol Rev       Date:  2004-12

7.  Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells.

Authors:  Eric Sulpice; Shunli Ding; Béatrice Muscatelli-Groux; Mathieu Bergé; Zhong Chao Han; Jean Plouet; Gérard Tobelem; Tatyana Merkulova-Rainon
Journal:  Biol Cell       Date:  2009-09       Impact factor: 4.458

8.  Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis.

Authors:  Verena Brucklacher-Waldert; Klarissa Stuerner; Manuela Kolster; Julia Wolthausen; Eva Tolosa
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

9.  Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease.

Authors:  D H Adams; P Burra; S G Hubscher; E Elias; W Newman
Journal:  Hepatology       Date:  1994-03       Impact factor: 17.425

Review 10.  Lymphocyte recruitment to the liver in alcoholic liver disease.

Authors:  Geoffrey Haydon; Patricia F Lalor; Stefan G Hubscher; David H Adams
Journal:  Alcohol       Date:  2002-05       Impact factor: 2.405

View more
  2 in total

1.  Biomarkers of endothelial dysfunction in alcoholic hepatitis.

Authors:  Tiffany Wu; Vijay Shah
Journal:  Hepatol Int       Date:  2021-05-27       Impact factor: 6.047

2.  Blood Biomarkers of Intestinal Epithelium Damage Regenerating Islet-derived Protein 3α and Trefoil Factor 3 Are Persistently Elevated in Patients with Alcoholic Hepatitis.

Authors:  Jing Yang; Fahim Syed; Ying Xia; Arun J Sanyal; Vijay H Shah; Naga Chalasani; Xiaoqun Zheng; Qigui Yu; Yongliang Lou; Wei Li
Journal:  Alcohol Clin Exp Res       Date:  2021-03-11       Impact factor: 3.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.